The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics

References

• Phase III Trial of Nexavar in patients with advanced melanoma does not meet primary endpointOnyx Pharmaceuticals, IncAccessed 12/4/2006 http://www.onyx-pharm.com/wt/page/pr_1165242111
   Google Scholar
• AmaravadiRKSchuchterLMKramerA20062006 ASCO Annual Meeting Proceedings Part IJournal of Clinical Oncology2418S8009
   Google Scholar
• AmiriPAikawaMDoveJ2006CHIR-265 is a potent selective inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutations97th AACR annual meetingWashington, DC
   Google Scholar
• BeeramMPatnaikARowinskyEK2005Raf: a strategic target for therapeutic development against cancerJ Clin Oncol2367719016170185
   PubMed Web of Science ®Google Scholar
• BennettDC2003Human melanocyte senescence and melanoma susceptibility genesOncogene223063912789281
   PubMed Web of Science ®Google Scholar
• BoultonTGCobbMH1991Identification of multiple extracellular signal-regulated kinases (ERKs) with antipeptide antibodiesCell Regul2357711654126
   PubMedGoogle Scholar
• BoultonTGNyeSHRobbinsDJ1991ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGFCell65663752032290
   PubMed Web of Science ®Google Scholar
• BroseMSVolpePFeldmanM2002BRAF and RAS mutations in human lung cancer and melanomaCancer Res626997700012460918
   PubMed Web of Science ®Google Scholar
• CarlomagnoFAnagantiSGuidaT2006BAY 43-9006 inhibition of oncogenic RET mutantsJ Natl Cancer Inst983263416507829
   PubMed Web of Science ®Google Scholar
• ChungNMGutierrezMTurnerML2006Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenibArch Dermatol14215101117116852
   PubMed Web of Science ®Google Scholar
• CohenCZavala-PompaASequeiraJH2002Mitogen-actived protein kinase activation is an early event in melanoma progressionClin Cancer Res837283312473582
   PubMed Web of Science ®Google Scholar
• CurtinJABusamKPinkelD2006Somatic activation of KIT in distinct subtypes of melanomaJ Clin Oncol244340616908931
   PubMed Web of Science ®Google Scholar
• DaviesHBignellGRCoxC2002Mutations of the BRAF gene in human cancerNature4179495412068308
   PubMed Web of Science ®Google Scholar
• DerCJKrontirisTGCooperGM1982Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma virusesProc Natl Acad Sci USA793637406285355
   PubMed Web of Science ®Google Scholar
• DickerAPVolkenandtMAlbinoAP1990Mutational analysis of human NRAS genes in malignant melanoma: rapid methods for oligonucleotide hybridization and manual and automated direct sequencing of products generated by the polymerase chain reactionGenes Chromosomes Cancer1257692278957
   PubMed Web of Science ®Google Scholar
• DrukerBJ2002Perspectives on the development of a molecularly targeted agentCancer Cell131612086885
   PubMed Web of Science ®Google Scholar
• EisenTAhmadTFlahertyKT2006Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysisBr J Cancer95581616880785
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWM2007Sorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med3561253417215530
   PubMed Web of Science ®Google Scholar
• FlahertyKT2006Chemotherapy and targeted therapy combinations in advanced melanomaClin Cancer Res122366s2370s16609060
   PubMed Web of Science ®Google Scholar
• FlahertyKTBroseMSchuchterL20042004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)Journal of Clinical Oncology2214S7507
   Google Scholar
• FletcherJARubinBP2007KIT mutations in GISTCurr Opin Genet Dev173717208434
   PubMed Web of Science ®Google Scholar
• GarrawayLAWeirBAZhaoX2005“Lineage addiction” in human cancer: lessons from integrated genomicsCold Spring Harb Symp Quant Biol70253416869735
   PubMedGoogle Scholar
• GarrawayLAWidlundHRRubinMA2005Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanomaNature4361172216001072
   PubMed Web of Science ®Google Scholar
• GotlibJ2006KIT mutations in mastocytosis and their potential as therapeutic targetsImmunol Allergy Clin North Am265759216931294
   PubMed Web of Science ®Google Scholar
• Gray-SchopferVWellbrockCMaraisR2007Melanoma biology and new targeted therapyNature445851717314971
   PubMed Web of Science ®Google Scholar
• Gray-SchopferVCKarasaridesMHaywardR2007Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibitedCancer Res67122917210691
   PubMed Web of Science ®Google Scholar
• HahnOStadlerW2006SorafenibCurr Opin Oncol186152116988583
   PubMed Web of Science ®Google Scholar
• Hall-JacksonCAEyersPACohenP1999Paradoxical activation of Raf by a novel Raf inhibitorChem Biol65596810421767
   PubMed Web of Science ®Google Scholar
• HaluskaFGTsaoHWuH2006Genetic alterations in signaling pathways in melanomaClin Cancer Res122301s2307s16609049
   PubMed Web of Science ®Google Scholar
• HeimbrookDHuberHStirdivantS1998Identification of potent, selective kinase inhibitors of RafAmerican Association of Cancer Research558
   Google Scholar
• HingoraniSRJacobetzMARobertsonGP2003Suppression of BRAF(V599E) in human melanoma abrogates transformationCancer Res63519820214500344
   PubMed Web of Science ®Google Scholar
• HockerTTsaoH2007Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variantsHum Mutat
   PubMed Web of Science ®Google Scholar
• HusseinMR2006Expression of KIT receptor tyrosine kinase protein in normal human skin: Preliminary observationsCell Biol Int
   PubMed Web of Science ®Google Scholar
• JemalASiegelRWardE2007Cancer statistics, 2007CA Cancer J Clin57436617237035
   PubMed Web of Science ®Google Scholar
• JohnstonSR2001Farnesyl transferase inhibitors: a novel targeted tnerapy for cancerLancet Oncol2182611905614
   PubMed Web of Science ®Google Scholar
• KarasaridesMChiloechesAHaywardR2004B-RAF is a therapeutic target in melanomaOncogene236292815208680
   PubMed Web of Science ®Google Scholar
• KhireURBankstonDBarbosaJ2004Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituentBioorg Med Chem Lett14783614741289
   PubMed Web of Science ®Google Scholar
• LackeyKCoryMDavisR2000The discovery of potent cRaf1 kinase inhibitorsBioorg Med Chem Lett10223610698440
   PubMed Web of Science ®Google Scholar
• LorussoPMAdjeiAAVarterasianM2005Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignanciesJ Clin Oncol2352819316009947
   PubMed Web of Science ®Google Scholar
• MacgregorJLSilversDNGrossmanME2007Sorafenib-induced erythema multiformeJ Am Acad Dermatol
   PubMed Web of Science ®Google Scholar
• MayoMWWangCYCogswellPC1997Requirement of NF-kappaB activation to suppress p 53-independent apoptosis induced by oncogenic RasScience2781812159388187
   PubMed Web of Science ®Google Scholar
• MesaRA2006Tipifarnib: farnesyl transferase inhibition at a crossroadsExpert Rev Anticancer Ther63131916503848
   PubMed Web of Science ®Google Scholar
• MorgilloFLeeHY2006Lonafarnib in cancer therapyExpert Opin Investig Drugs1570919
   PubMed Web of Science ®Google Scholar
• Niculescu-DuvazIRomanEWhittakerSR2006Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar leadJ Med Chem494071616392826
   PubMed Web of Science ®Google Scholar
• OuyangBKnaufJASmithEP2006Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivoClin Cancer Res1217859316551863
   PubMed Web of Science ®Google Scholar
• PankaDJWangWAtkinsMB2006The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cellsCancer Res6616111916452220
   PubMed Web of Science ®Google Scholar
• PickleLWHaoYJemalA2007A new method of estimating United States and state-level cancer incidence counts for the current calendar yearCA Cancer J Clin57304217237034
   PubMed Web of Science ®Google Scholar
• RatainMJEisenTStadlerWM2006Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinomaJ Clin Oncol2425051216636341
   PubMed Web of Science ®Google Scholar
• Rodriguez-VicianaPTetsuOOdaK2005Cancer targets in the Ras pathwayCold Spring Harb Symp Quant Biol70461716869784
   PubMedGoogle Scholar
• RoussidisAETheocharisADTzanakakisGN2007The Importance of c-Kit and PDGF Receptors as Potential Targets for Molecular Therapy in Breast CancerCurr Med Chem147354317346159
   PubMed Web of Science ®Google Scholar
• SatyamoorthyKLiGGerreroMR2003Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulationCancer Res63756912591721
   PubMed Web of Science ®Google Scholar
• SchnadigIDBlankeCD2006Gastrointestinal stromal tumors: imatinib and beyondCurr Treat Options Oncol74273717032555
   PubMedGoogle Scholar
• SchreckRRappUR2006Raf kinases: oncogenesis and drug discoveryInt J Cancer11922617116894562
   PubMed Web of Science ®Google Scholar
• SmalleyKSEisenTG2003Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cellsInt J Cancer1051657512673674
   PubMed Web of Science ®Google Scholar
• SolitDBGarrawayLAPratilasCA2006BRAF mutation predicts sensitivity to MEK inhibitionNature4393586216273091
   PubMed Web of Science ®Google Scholar
• SosmanJAPuzanovI2006Molecular targets in melanoma from angiogenesis to apoptosisClin Cancer Res122376s2383s16609062
   PubMed Web of Science ®Google Scholar
• SteingrimssonECopelandNGJenkinsNA2004Melanocytes and the microphthalmia transcription factor networkAnnu Rev Genet3836541115568981
   PubMed Web of Science ®Google Scholar
• StrumbergD2005Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatmentDrugs Today (Barc)417738416474853
   PubMed Web of Science ®Google Scholar
• StuartDAardalenKLorenzanaE2006Characterization of a novel Raf kinase inhibitor that causes target dependent tumor regression in human melanoma xenografts expressing mutant B-Raf97th AACR annual meetingWashington, DC
   Google Scholar
• TakleAKBrownMJDaviesS2006The identification of potent and selective imidazole-based inhibitors of B-Raf kinaseBioorg Med Chem Lett163788116260133
   PubMed Web of Science ®Google Scholar
• TomitaY1994The molecular genetics of albinism and piebaldismArch Dermatol13035588129415
   PubMedGoogle Scholar
• TsaiJZhangJBremerR2006Development of a novel inhibitor of oncogenic B-RAF97th AACR annual meetingWashington, DC
   Google Scholar
• TsaoHAtkinsMBSoberAJ2004Management of cutaneous melanomaN Engl J Med351998101215342808
   PubMed Web of Science ®Google Scholar
• TsaoHGoelVWuH2004Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanomaJ Invest Dermatol1223374115009714
   PubMed Web of Science ®Google Scholar
• UgurelSHildenbrandRZimpferA2005Lack of clinical efficacy of imatinib in metastatic melanomaBr J Cancer92139840515846297
   PubMed Web of Science ®Google Scholar
• UribePWistubaIIGonzalezS2003BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skinAm J Dermatopathol253657014501284
   PubMed Web of Science ®Google Scholar
• VenetsanakosEStuartDTanN2006CHIR-265, a novel inhibitor that targets B-Raf and VEGFR, shows efficacy in a broad range of preclinical models97th AACR annual meetingWashington, DC
   Google Scholar
• VeroneseMLMosenkisAFlahertyKT2006Mechanisms of hypertension associated with BAY 43-9006J Clin Oncol241363916446323
   PubMed Web of Science ®Google Scholar
• WanPTGarnettMJRoeSM2004Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAFCell1168556715035987
   PubMed Web of Science ®Google Scholar
• WhitwamTVanbrocklinMWRussoME2007Differential oncogenic potential of activated RAS isoforms in melanocytesOncogene
   PubMed Web of Science ®Google Scholar
• WilhelmSChienDS2002BAY 43-9006: preclinical dataCurr Pharm Des82255712369853
   PubMed Web of Science ®Google Scholar
• WilhelmSMCarterCTangL2004BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisCancer Res64709910915466206
   PubMed Web of Science ®Google Scholar
• WymanKAtkinsMBPrietoV2006Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacyCancer10620051116565971
   PubMed Web of Science ®Google Scholar